GlassScriptPhysician profile
Therese Casas
NPI 1588773790
$15,858.16
in general payments reported to CMS, 2019-2025
36 companies · $4,566 in 2025
The $4,566 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,766 · 2022: $2,412 · 2023: $3,368 · 2024: $2,746 · 2025: $4,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,480 · Education: $700 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,480.18 |
| Education | $700.06 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,746.83 | 2021-2025 | Siliq, Cabtreo, Jublia |
| Sun Pharmaceutical Industries INC. | $1,375.19 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Janssen Biotech, INC. | $1,070.44 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Dermavant Sciences, INC. | $1,052.04 | 2022-2024 | Vtama |
| Abbvie INC. | $1,033.38 | 2021-2025 | |
| Journey Medical Corporation | $1,005.62 | 2021-2025 | Emrosi |
| Amgen INC. | $974.13 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $764.59 | 2021-2025 | Aklief, Nemluvio, Twyneo |
| Ucb, INC. | $638.31 | 2021-2025 | Bimzelx, Cimzia |
| Almirall LLC | $607.22 | 2021-2025 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $589.86 | 2022-2025 | Sotyktu |
| Pfizer INC. | $571.63 | 2021-2025 | |
| Lilly USA, LLC | $531.39 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Genzyme Corporation | $515.54 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $458.98 | 2023-2025 | Zoryve |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $448.77 | 2021-2025 | Dupixent |
| Organon LLC | $414.60 | 2025 | Vtama |
| Leo Pharma INC. | $370.26 | 2021-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $317.90 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $281.40 | 2022-2025 | |
| Vyne Pharmaceuticals INC. | $217.21 | 2021 | |
| Incyte Corporation | $210.79 | 2021-2025 | Opzelura |
| Botanix Sb INC | $201.35 | 2025 | Sofdra |
| Epi Health, LLC | $188.08 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.82 | 2023-2025 | Spevigo |
| Convatec INC. | $38.21 | 2024-2025 | |
| Genentech USA, INC. | $31.29 | 2022-2024 | Erivedge |
| Nabriva Therapeutics, Plc | $25.04 | 2021 | |
| Organogenesis INC. | $19.42 | 2024 | |
| Blueprint Medicines Corporation | $18.50 | 2024 | Ayvakit |
| Sandoz INC. | $16.58 | 2021 | |
| Fidia Pharma USA INC. | $15.75 | 2024 | |
| Medimetriks Pharmaceuticals, INC. | $15.69 | 2025 | Clindacin Etz |
| Dermira, INC. | $14.94 | 2021 | |
| Biofrontera INC. | $14.01 | 2021 | |
| Mission Pharmacal Company | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Therese Casas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.